In 2016, Christopher Garabedian earned $979.00K in total compensation at Sarepta Therapeutics, Inc., including $550.00K salary and $429.00K bonus. Most recently acquired 800 shares in Feb 2015. Currently holds stock worth $722.55K. Led Sarepta Therapeutics, Inc. as CEO for 4 years.
Compensation History
Annual executive compensation data for Christopher Garabedian, including salary, bonuses, and stock awards.
Year
2016
Total Compensation
$979.00K
Salary
$550.00K
Bonus
$429.00K
Other
$0.00
Salary
$550.00KBoard Justification
The compensation committee aimed to align executive compensation with company performance and market competitiveness, focusing on attracting and retaining top talent in a challenging regulatory environment.
Bonus
$429.00KBoard Justification
Cash bonus based on achievement of corporate goals, targeted at 65% of base salary after his appointment as CEO in September 2016.
Other Compensation
$0.00Board Justification
No additional compensation was reported for the CEO in 2016.
Restricted Stock
Board Justification
No stock was reported as vested in 2016 for the CEO.
Performance Metrics
Performance metrics included securing FDA accelerated approval for EXONDYS 51 and achieving corporate goals related to the commercialization of the product.
Christopher Garabedian
Ex-CEO of Sarepta Therapeutics, Inc.
Education
MBA from Harvard Business School
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
March 15, 1968 - 57 years ago
CEO of Sarepta Therapeutics, Inc. for
4 years 10 months (Jul 2011 - Jun 2016)
Previous Experience
President of Sarepta Therapeutics, Inc.
Other Sarepta Therapeutics, Inc. CEOs
Holdings
Track Christopher Garabedian's stock holdings and portfolio value over time.
Insider Trading
Christopher Garabedian's recent stock transactions, purchases, and sales filed with the SEC.
$9.45K
SRPT at $11.82/share
Feb 27, 2015
Purchase
Rivals
Compare Christopher Garabedian with competitor CEOs and industry peers.